Company creation and early-stage investing in life sciences: A Novo Seeds perspective
Stephan Christgau, Senior Partner
Novo Seeds.
Stephan Christgau, Senior Partner
Novo Seeds.
Nomination deadline 11th April 2019
John Cassidy
Investment Associate
Arix Bioscience plc
Robert James
Managing Partner
Sixth Element Capital
Will this trend continue? Analysis of Biopharma M&A in 2018 (and previous years)
Since 2011, over 40 European healthcare start-ups have used equity crowdfunding, rather than the traditional venture capital (VC) route…
New advances in technology are having a tremendous impact through the entire healthcare spectrum.
Dr Niall Kirk profiles this alternative source of capital while introducing readers to the online crowdfunding marketplace
Designed to help high-potential businesses understand the role of capital markets and how they can reach the next stage of their growth.
Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients
PART TWO: The changing role of consensus
PART ONE: The changing role of Consensus. The new MiFID II rules are expected…
It is almost six months since MIFID II went live, Optimum Strategic Communications…
Building billion-dollar healthcare businesses in Europe is dependent on a number of success factors…
Global and European healthcare investors were generally optimistic feeling that money invested into the life sciences industry…
Whilst we are probably waiting for the biotech IPO cycle to bottom out in Europe, secondary financings have been going strong…
Europe is missing many companies scaled up to this market cap bracket, partly because any pretenders to the title have been acquired…
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com